Skip to content
Clinical Trials – home
Not yet recruiting

Safety and Efficacy of GSK5764227 with Abiraterone Acetate and Enzalutamide in Metastatic Castration‑Resistant Prostate Cancer Patients

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on Metastatic Castration-resistant Prostate Cancer, a form of prostate cancer that has spread to other parts of the body and continues to grow even when testosterone levels are low. The investigational therapy is a B7-H3 Antibody Drug Conjugate called risvutatug rezetecan, which is given by an intravenous infusion and is designed to carry a chemotherapy payload directly to cancer cells. Participants may also receive standard oral medicines such as enzalutamide or abiraterone acetate, which are commonly used to block hormone signals that fuel prostate cancer, and they may have previously been treated with a class of chemotherapy drugs known as Taxane and with ARPI (drugs that block the androgen receptor pathway).

The purpose of the study is to compare the effectiveness of risvutatug rezetecan with best supportive care, with or without continued hormone‑blocking therapy, in men whose disease has returned after earlier treatments.

Participants are randomly assigned to receive either the new intravenous medication or the standard oral regimen plus supportive care. Treatment is given over several cycles, with regular clinic visits for safety checks, blood tests, and imaging scans to monitor disease status. After the treatment period, participants continue to be followed for additional months to assess long‑term outcomes and any side effects.

The research process

The trial runs in 11 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization and Treatment Assignment

    After joining the study you will be randomly assigned to receive either the investigational drug risvutatug rezetecan (referred to as GSK5764227) or a standard oral medication.

    The standard medication may be enzalutamide (known as Xtandi) or abiraterone acetate (known as Zytiga), depending on the study arm.

  2. Step 2

    Baseline Assessments

    Before starting any treatment you will undergo blood tests, imaging scans, and a questionnaire about pain and quality of life.

    These assessments establish a starting point for later comparison of disease status and symptom changes.

  3. Step 3

    Start of Treatment – Investigational Arm

    If you are assigned to the investigational arm you will receive GSK5764227 by intravenous infusion.

    The dose is 8 mg per kilogram of body weight and is given at the start of each treatment cycle as defined by the study schedule.

  4. Step 4

    Start of Treatment – Comparator Arm

    If you are assigned to the enzalutamide comparator you will take four 40 mg tablets each day (total 160 mg) by mouth.

    If you are assigned to the abiraterone acetate comparator you will take two 500 mg tablets each day (total 1000 mg) by mouth.

  5. Step 5

    Ongoing Treatment Cycles

    You will continue the assigned medication for each subsequent cycle.

    For the investigational arm you will return for additional intravenous infusions according to the study schedule.

    For the oral comparators you will receive a supply of tablets to take daily until the next scheduled visit.

  6. Step 6

    Regular Clinic Visits and Safety Checks

    At each visit you will have blood drawn to monitor organ function and prostate‑specific antigen (PSA) levels.

    Your health care team will ask about any side effects and may adjust the dose or pause treatment if needed.

  7. Step 7

    Imaging Assessments

    Imaging scans (such as CT or MRI) will be performed at predefined intervals to check for disease progression.

    Progression is defined by the study as new tumor growth on the scan or death from any cause.

  8. Step 8

    Pain and Quality‑of‑Life Monitoring

    You will complete the Brief Pain Inventory – Short Form (BPI‑SF) questionnaire regularly.

    A diary may be used to record any opioid pain medication you take, which helps evaluate pain progression.

  9. Step 9

    Management of Adverse Events

    If you experience side effects, the study team may modify the dose, delay the next dose, or discontinue treatment, following safety guidelines.

    All changes are recorded and reported as part of the study’s safety evaluation.

  10. Step 10

    End of Treatment

    Treatment will stop if disease progression is confirmed, side effects become unacceptable, or the planned number of cycles is completed.

    You will be informed of the reason for stopping the medication.

  11. Step 11

    Post‑Treatment Follow‑Up

    After stopping the study drug you will continue to have periodic visits for safety monitoring and survival assessment.

    These follow‑up visits may include blood tests, imaging, and questionnaires to track long‑term outcomes.

Who can join the trial?

5 criteria

  • You must be at least 18 years old (or the legal age to give consent) when you sign the study agreement.
  • You need to have a prostate cancer that has been confirmed by a microscope test of tissue (histology) or cells (cytology), specifically an adenocarcinoma of the prostate (a common type of prostate cancer).
  • Your overall health score, called the ECOG Performance Status, must be 0 or 1, meaning you are fully active or able to do light work, and this score must not have gotten worse in the two weeks before you are randomly assigned to a treatment group.
  • You should have a life expectancy of at least four months, meaning doctors expect you to live for at least that length of time.
  • Your body’s major organs (like liver, kidneys, and blood‑forming system) must be working well enough, described as having adequate organ function.

Who cannot join the trial?

9 criteria

  • Having a tissue test that shows a type of prostate cancer called small cell or neuroendocrine carcinoma, a mix of different cancer types, or any cancer type that is not the usual adenocarcinoma (the most common form of prostate cancer).
  • Being known to have dMMR (deficient mismatch repair), MSI‑H (high microsatellite instability), or TMB‑H (high tumor mutational burden) and being eligible for a special immunotherapy called an immune checkpoint inhibitor.
  • Having any other cancer that has gotten worse or needed active treatment within the past 24 months.
  • Having had a major operation, including prostate procedures (except a simple biopsy), within 28 days before the study starts.
  • Having significant bleeding problems or a strong tendency to bleed within one month before the first dose.
  • Having an active infection that needs medicines that work throughout the whole body (systemic treatment) or having known HIV infection.
  • Having untreated cancer that has spread to the brain or central nervous system (CNS) or having brain/CNS cancer that has gotten worse.
  • Having taken medicines that suppress the immune system (systemic immunosuppressive agents) within 30 days before the first dose.
  • Having previously received a special type of drug called an antibody‑drug conjugate (ADC) that contains a TOPO1‑inhibitor (a chemotherapy agent) or a drug that targets B7 H3 (a protein) or a bispecific antibody (an antibody that can bind two targets).
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Xtandi is a tablet taken by mouth that contains the medicine enzalutamide. It works by blocking the action of male hormones that can help prostate cancer grow. In this study it is used as a standard treatment to compare against the new drug.

GSK5764227 is an experimental medication that is given through an IV infusion. It is a type of antibody‑drug conjugate that targets a protein called B7‑H3 on cancer cells. The trial is testing whether this new therapy can slow or shrink the cancer in men whose disease has returned after other treatments.

ZYTIGA is a tablet taken by mouth that contains abiraterone acetate. It works by lowering the production of male hormones that can stimulate prostate cancer. In the trial it serves as another standard treatment used for comparison with the experimental drug.

Best supportive care (BSC) refers to routine medical care that helps manage symptoms and maintain quality of life. In this study participants may receive BSC alone or together with other hormone‑targeting drugs, providing a baseline against which the new therapy is measured.

What is already known about the treatment

  • Xtandi (enzalutamide)

    This medication is taken as a film‑coated tablet taken by mouth. It is an approved drug widely used in the treatment of advanced prostate cancer and is well documented in medical literature. It works by blocking androgen receptors, preventing male hormones from stimulating cancer cells. It belongs to the class of anti‑androgen agents.

  • GSK5764227

    This investigational drug is supplied as a powder that is mixed for intravenous infusion. It is currently an experimental therapy under study and has not yet received market approval. It targets the B7‑H3 protein on cancer cells, delivering a toxic payload that kills the cells while sparing normal tissue. It is classified as an antibody‑drug conjugate (ADC).

  • Zytiga (abiraterone acetate)

    This medication comes as a film‑coated tablet taken orally. It is an approved treatment for metastatic castration‑resistant prostate cancer and is well described in the literature. It blocks an enzyme needed to make testosterone, lowering hormone levels that fuel tumor growth. It is classified as a steroidal CYP17 inhibitor.

Investigated diseases

Metastatic castration-resistant prostate cancer - Metastatic castration‑resistant prostate cancer is a form of prostate cancer that continues to grow even when testosterone levels are very low. The disease has already spread beyond the prostate to distant sites such as bone or lymph nodes. Cancer cells in this stage no longer respond to hormone‑lowering therapies and keep proliferating. Tumor growth can be seen on imaging as new or enlarging lesions. The disease may also cause rising levels of prostate‑specific antigen, indicating ongoing activity. Over time, lesions can increase in size and affect organ function.
Trial detailsLast updated 17 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2026-525558-13-00Protocol code300145Estimated enrolment596 patientsSponsorGlaxosmithkline Research & Development Limited

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.